Soaring drug development costs, increasingly stringent regulatory requirements, and demanding market access environments have necessitated that pharmaceutical companies examine their research processes in order to provide novel and meaningful solutions for patients. In this paper, we describe an initiative that aims to incorporate a better appreciation of the exam room experience of both patients and practitioners into the drug development pathway from the earliest point of research. Focusing on 4 core pillars-medical value, patient need, scientific rationale, and market environment-an integrated analytic process is undertaken so as to facilitate early identification of ideal target populations and criteria that will need to be met for successful entry into the treatment continuum. Collaborative interactions with other specialist roles within the organization are also described. It is argued that understanding the unmet medical need and the risks and opportunities inherent in different development scenarios can help direct early research so as to encourage truly transformative health care solutions.
Introduction
Successful development of new therapeutic agents has become increasingly difficult. More complex disease targets, challenging timelines, and intense competition have made companies, large and small, wary of failure.
Equally alarming is the steadily rising cost to develop new drugs estimated at $2.9 billion (2013 dollars) from test tube to licensure, 1 the low probability of clinical success with 11.83% achieving regulatory approval, 1 and declining returns on investments, from 10.1% in 2010 to 4.2% in 2015. 2 Declining productivity has been compounded by increasingly stringent regulatory requirements. As of December 2016, only 19 new medicines had been approved in the US, down from 45 in 2015 and 41 in 2014. Between 2000 and 2012, 47% of applications required one or more resubmissions, resulting in a median delay of 435 days to approval. Failure to prove efficacy, a common reason for rejection of first-time applications, is attributed in part to "choice of study endpoints that do not adequately reflect clinically meaningful benefit to patients." 3 Further highlighting the need to better understand the patient perspective, the Pharma 2020 publication 4 points out that "every company will have to be more selective about the diseases it addresses," "be more discriminating about the candidates it advances through the pipeline," and "transform its corporate culture to foster innovation and address the needs of patients, payers, and providers in the 21st century."
To this end, even when successful development occurs, regulatory bodies are looking for products that are not only safe and effective but also differentiated from currently available medicines. A skeptical insurance industry is looking for greater real world benefit and is increasingly unwilling to pay for medicines that provide small incremental improvements over cheaper alternatives. The future R&D landscape will be dominated by those who can focus on significant unmet medical need and deliver transformative health care solutions to patients, dramatically improving outcomes. This position is further reinforced by regulatory body decision making and position statements. 5 In 2013 the European Medicines Agency (EMA) acknowledged the importance of involving patients "as critical stakeholders in the regulatory process and works extensively with patient and consumer representatives." 6 FDA's Patient Engagement Advisory Committee and PatientFocused Drug Development meetings reflect a similar concern to enhance the patient's voice in drug review and development.
Faced with these issues, we examined processes that would yield better insight into unmet need in specific disease areas and specific patient populations, deepening our understanding of the medical value of new entrants into the treatment continuum. While much of the industry-wide patient engagement effort to date has been in the clinical trial space, our express aim was to incorporate into the development pathway, from the earliest point in research, a better appreciation of the exam room experience of both patients and practitioners. To that end, a process was designed to analyze pertinent interdependent pieces of information that would focus on the patient perspective and the medical value of new medicines, in order to arrive at a broad-based analysis of risk and opportunity. The objective was to redress the historical scientific "can we" research bias with a real world "should we," value-based paradigm ( Figure 1 ). As this approach evolved and gained traction in the organization, the Medical Intelligence and Patient Perspective Group (MIPP) was established to provide support to project teams in shaping their research direction.
Guiding Principles
MIPP work is designed to assess assets in research and early development from the point of compound identification to proof of concept (PoC). While science is the key driver of research, and scientific credibility a pre-requisite to any development, MIPP aims to introduce into the discourse, at a very early stage of development, a keen understanding of the disease target, the current standard of care (SoC), the unmet need in the patient population of interest, the likely entry point into the treatment continuum and the necessary medical value of a new entrant. Rather than simply provide teams with information, the objective is to integrate information into an analysis which will enable project teams to better understand the opportunities and risks associated with an asset-disease linkage. The basis of the work processes developed by the MIPP group incorporates the exam room into the developmental process enabling patient, clinician, scientific, competitive, and market information to be made actionable from the earliest point in research.
Process Overview
The MIPP team is composed of highly specialized health care professionals representing wide-ranging areas of expertise. Members include clinicians, scientists, pharmacists, health economists and individuals with commercial and market access experience. Importantly, the team utilizes internal capabilities, reaching deeply into the organization to tap into areas such as clinical development and translational medicine.
The core of the MIPP process is based on an analysis of 4 primary areas of research: scientific rationale, patient need, medical value, and competitive/market assessments. These research categories, weighted depending on the asset's stage in the developmental cycle, are critical to achieving the appropriate balance between developable sciences on the one hand and the medical value and patient need on the other ( Figure 2 ).
It is this integration of the science with a determination of medical value and patient unmet need, together with its application to early research, which differentiates the MIPP method as a decision tool. Science, need, and value are aligned with an understanding of currently available treatments, the competitive environment, and an evaluation of potential entry points into the treatment continuum-all of which are critical components in the determination of subsequent market potential.
Ultimately, this information is utilized by project teams to align the developmental process with the identified opportunities, and by decision-making committees as part of an informational package to promote projects of high value and terminate those unlikely to succeed.
Core Components of Analysis Scientific Rationale
Critical understanding of the scientific basis of the asset is the starting point. No science equals no new medicine. Based on this mechanism, potential disease targets of interest are generated. Always giving priority to the need-value assessment in each disease area under consideration, the mode of action, translatability and developability are all interrogated in order to determine the optimal disease target and patient population. In this way, the science and the disease are aligned in an integrated and cohesive approach from the earliest stages of drug discovery, avoiding the "stuttering" input of information that often complicates decision making regarding asset viability. The patient perspective is considered to be so central to the MIPP assessment that an R&D Patient Engagement Portal has been created to facilitate and standardize formal interviews with patients. The portal is a centralized, monitored platform open to any internal R&D stakeholder designed to create a low barrier process to facilitate the scheduling of a patient meeting. It is intended to reinforce and promote the corporate emphasis on the patient perspective. It is at the same time a key component in MIPP efforts to bring the patient into the core of the internal development process in a reproducible and sustainable way.
In nearly all workstreams, patient interviews are scheduled and the information obtained is directly integrated into the MIPP analysis. This information is critically important to understanding, in the defined population, the current impact of SoC, the needs that exist beyond SoC, and what patients "wish" for to fill gaps in care. Interaction with patient advocacy groups and review of social media are additional sources informing the MIPP patient perspective. While this is not meant to be exhaustive, it does provide critical and necessary insight into the current life of individuals dealing with acute and chronic illness. The insights gained are embedded into the analysis of what would be required of a new agent in order to satisfy current unmet patient need.
Medical Value
The medical value of an asset is determined primarily by its capacity to fill a gap in the management of a disease. Examined here is the greatest need in the treatment continuum, and the specific characteristics required of an asset in order to successfully enter at this point. We look extensively at SoC and interview practicing physicians in order to better understand what they believe are important attributes for a new agent in a particular disease area. In their view, is there appropriate assetdisease alignment?
Meeting regulatory body requirements is an obvious prerequisite to successful development of a new asset. Although MIPP is not directly involved in clinical development or regulatory assessments, the team does work with internal experts to examine regulatory precedents and likely developmental/ outcome expectations, which are then integrated into the analysis. Aligning these expectations with the asset's actual performance in later clinical study is a critical piece in the decision tree when evaluating the developmental program.
Competitive/Market Assessment
Understanding the competitive landscape, a high level view of patient demographics, current cost of care in different health care environments and market trends are important pieces of information that are sometimes reserved for more mature assets. However, we believe the earlier this information is integrated into the project team's thinking the better the understanding of the potential impact of the asset in development. It is imperative to note that early in the developmental cycle this portion of the assessment, compiled by team experts who utilize information from numerous databases and publications, is primarily informational. Far more important at this stage of the analysis are valid science, an understanding of need and value, and the determination of logical points of entry in the treatment continuum.
As assets proceed in development and clinical data are generated, the foundational MIPP evaluation is handed off to new product and commercial teams for more complete and substantial market assessments. 
Collaborations
As pointed out earlier, MIPP collaborates extensively with internal experts within research and development to provide project teams with a temporally aligned and thorough analysis. However, equally important are alignments with other internal teams that sit outside of research and development but may provide project input later in the developmental cycle. To provide seamless support as assets move through research and early development, MIPP has created a continuum of collaborations that includes New Product Planning, Clinical Trial Operations, Health Economics, and Device Development (Figure 3 ). To facilitate complete transparency, regular monthly meetings take place with each of our partners to share work that is ongoing, work that is planned and results of analyses completed. This information exchange is bidirectional and eliminates any redundancies or duplication of outputs. As the unique value of the MIPP is increasingly recognized in the organization, more focused queries and requests for refreshed analyses are being received as the asset characteristics become clearer and the standard of care evolves.
Medical Intelligence: Evolution
MIPP was established via a ground up approach. There was no organizational mandate that drove this process. Instead, individual project teams were engaged, the concept explained, and an analysis delivered that could be directly utilized in decision making. As work with one team was completed, another request would be received. Soon inquiries began to come in from a range of therapeutic areas, then from different geographic footprints. Within 1.5 years, the process was global and supporting all therapeutic areas.
It is important to note that while we are openly unbiased in our approach, we made it clear to project teams that we perceived our role as supportive, and not decisional. Final use of the information contained in our analysis was at their discretion.
Bearing in mind that review committees were aware of the analyses and might even ask for MIPP opinion, most teams chose to integrate the information into their reports whether or not they agreed with the outcome and recommendations. As R&D structures within the organization have evolved, MIPP representation has specifically been requested on new platforms.
Assessment of Impact
In the first 3 years of operation, MIPP has evaluated 72 disease areas and supported 34 project teams. Given the slow pace of drug development, it is still too early to assess the long-term impact of these assessments. In order to monitor the perceived value of our work and to ensure continuous improvement within the group, we have instituted 2 processes for qualitative and quantitative feedback.
First, after each analysis is delivered a member of the MIPP team interviews the project/science lead in order to determine their opinion of the MIPP output, whether or not they found it helpful and how it could be improved. In addition, a few weeks thereafter, a survey is sent to members of the requesting team asking specific questions regarding practical usefulness, for example: Was MIPP analysis used in your decision making? Was information from the analysis used in subsequent presentations? Did MIPP analysis change your decision making? The responses are anonymous, allowing for open and free input. While this process is relatively new, and feedback limited, teams have overwhelmingly indicated that the input provided has been critical to decision making. It has been used to strengthen the rationale and provide support when presenting to strategic leadership committees. Most interesting was the observation that where poorly developed scientific arguments have converged with an MIPP finding of limited medical value, this has facilitated motivations for program discontinuation.
While we recognize that decisions regarding progression of a research asset are complex and influenced by a number of factors, we nevertheless have been convinced by our preliminary surveys that the MIPP approach has been an important ingredient in the decision tree. The feedback from project teams has been universally positive, and repeat requests have been received regardless of whether the analysis was supportive or in conflict with the their initial position. A more rigorous quantitative assessment of outcomes is ongoing.
One additional point regarding the integration of the patient voice into the assessments: this has been seen as an enormously impactful component. Project team members who attend the patient interviews have felt it positively influenced the work of their teams and helped significantly in their understanding of the disease target of interest. Feedback from patients who have been involved has been equally favorable. Processes have been put in place to maintain these early relationships with patients and patient groups for the longer-term. There are many details around this component of the MIPP process that will be discussed elsewhere.
Next Steps
To what extent are MIPP assessments able to impact the success of an approved product after launch? It will take additional time to definitively evaluate the longer-term impact; however, it is clear that a better understanding of the patient perspective is an important component of product success. In a 2014 publication, McKinsey and Company assessed 210 drug launches. Of those, twothirds failed to meet pre-launch market penetration. Those that did poorly at launch continued to do poorly despite efforts to change course. The authors point out that the difficulty lies in understanding differentiation of the new entrant: "companies must ensure they quickly understand the market's unmet needs." 7 Continued understanding of asset-disease alignment with a focus on the need-value linkage is proving an important point of collaboration with our commercial colleagues-those tasked with new product acquisition as well as those whose primary focus is commercialization of internally developed new medicines. As the MIPP process has evolved and matured we are receiving increasing numbers of requests from within these groups. The value of the exam-room perspective is evident in the late developmental stages as a deep understanding of the target population provides additional clarity of the market opportunities. Additionally, the learnings from these interactions have realized significant organizational value: aligning the strengths of internal groups, establishing a process for life cycle management evaluations and greater sharing of information from research through licensure.
Conclusion
MIPP grew out of recognition of an increasing need to insert the patient perspective firmly into the discourse at the earliest stage of drug development. By providing early asset-disease alignment and balancing the science with the unmet medical need, MIPP has facilitated early identification of potential target populations and articulated the risks, opportunity, and criteria for success inherent in different development scenarios. The integration of the science with medical value and unmet patient need has enabled the creation of clear, clinically meaningful, real-world go/no-go points so that projects that are unlikely to differentiate from SoC can be redirected, or terminated, as early as possible in the developmental process.
Moving forward, organizations will need to routinely incorporate the patient perspective into the research process from the earliest point in the continuum to be successful. It is important that the patient voice not only be informational but applied to an appropriate vehicle that can operationalize it into developmental plans. The identification of patient need and clarity around the medical value of new assets must balance the ability to execute on the science if we are to operate successfully in the current drug development environment.
